摘要
目的:评价恩替卡韦对慢性乙型肝炎(CHB)患者初治的近期疗效,为临床合理用药提供参考。方法:将68例CHB患者随机分为两组,每组34例,以接受拉米夫定治疗者为A组,以接受恩替卡韦治疗者为B组;评价两组患者治疗6周后ALT、AST、GGT及HBV-DNA含量改善情况,并对接受3月治疗后两组HBV-DNA转阴率作一对比。结果:治疗6周后B组患者ALT、AST、GGT及HBV-DNA含量显著优于A组(P<0.05);B组患者治疗3月后HBV-DNA阳性率显著低于A组(P<0.05)。结论:恩替卡韦可有效地提高CHB患者的近期疗效。
Objective： To evaluate the recent clinical efficacy of entecavir in patients with chronic hepatitis B（CHB） and to rovide a reference for clinical rational medication. Methods： Sixty-eight patients of CHB were randomly divided into two groups（each group of 34 cases）, lamivudine therapy was in group A and entecavir therapy was in group B. Two groups patients were treated after 6 weeks, the situation of ALT, AST, GGTP, GGT and HBV DNA levels were evaluated. The improvement of HBV-DNA overcast rate of the two groups patients after 3 months treatment was analyzed. Results： The ALT, AST, GGT and HBV DNA levels of Group B patients after treatment of 6 weeks were significantly better than those of group A（P0.05）. The HBV- DNA positive rates of Group B patients after treatment of 3months were significantly lower than those of group A（P0.05）. Conclusion： Entecavir can obviously raise the recent clinical efficacy in Patients with Chronic Hepatitis B
出处
《抗感染药学》
2015年第1期105-107,共3页
Anti-infection Pharmacy
关键词
恩替卡韦
CHB
近期疗效
entecavir
CHB
The recent clinical efficacy
